iRECIST and atypical patterns of response to immuno-oncology drugs

Gelijkaardige items

• iRECIST and atypical patterns of response to immuno-oncology drugs
  door: Emiliano Calvo, et al.
  Gepubliceerd in: (2022-06-01)
• Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
  door: James L Gulley, et al.
  Gepubliceerd in: (2022-02-01)
• RECIST 1.1 CRITERIA IN THE ASSESSMENT OF LUNG TUMORS
  door: O. N. Chernova, et al.
  Gepubliceerd in: (2017-03-01)
• RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
  door: Christelle de La Fouchardière, et al.
  Gepubliceerd in: (2020-10-01)
• Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
  door: Manoj Gupta, et al.
  Gepubliceerd in: (2022-03-01)